title: Mechanism and significance of cell type-dependent neutralization of flaviviruses.
abstract: The production of neutralizing antibodies (NAbs) is a correlate of protection for many human vaccines, including currently licensed vaccines against flaviviruses. NAbs are typically measured using a plaque reduction neutralization test (PRNT). Despite its extensive use, parameters that impact the performance of the PRNT have not been investigated from a mechanistic perspective. The results of a recent phase IIb clinical trial of a tetravalent dengue virus (DENV) vaccine suggest that NAbs, as measured using a PRNT performed with Vero cells, do not correlate with protection. This surprising finding highlights the importance of understanding how well the PRNT captures the complexity of the NAb response to DENV. In this study, we demonstrated that the structural heterogeneity of flaviviruses arising from inefficient virion maturation impacts the results of neutralization assays in a cell type-dependent manner. Neutralization titers of several monoclonal antibodies were significantly reduced when assayed on Vero cells compared to Raji cells expressing DC-SIGNR. This pattern can be explained by differences in the efficiency with which partially mature flaviviruses attach to each cell type, rather than a differential capacity of antibody to block infection. Vero cells are poorly permissive to the fraction of virions that are most sensitive to neutralization. Analysis of sera from recipients of live-attenuated monovalent DENV vaccine candidates revealed a strong correlation between the sensitivity of serum antibodies to the maturation state of DENV and cell type-dependent patterns of neutralization. Cross-reactive patterns of neutralization may be underrepresented by the "gold-standard" PRNT that employs Vero cells.
  
  
  OBJECTIVE
  Cell type-dependent patterns of neutralization describe a differential capacity of antibodies to inhibit virus infection when assayed on multiple cellular substrates. In this study, we established a link between antibodies that neutralize infection in a cell type-dependent fashion and those sensitive to the maturation state of the flavivirus virion. We demonstrated that cell type-dependent neutralization reflects a differential capacity to measure neutralization of viruses that are incompletely mature. Partially mature virions that most efficiently bind maturation state-sensitive antibodies are poorly represented by assays typically used in support of flavivirus vaccine development. The selection of cellular substrate for neutralization assays may significantly impact evaluation of the neutralization potency of the polyclonal response. These data suggest that current assays do not adequately capture the full complexity of the neutralizing antibody response and may hinder the identification of correlates of protection following flavivirus vaccination.
authors.affiliation: Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Swati
authors.initials: S
authors.lastname: Mukherjee
authors.affiliation: Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Dowd
authors.affiliation: Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Manhart
authors.affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Julie E
authors.initials: JE
authors.lastname: Ledgerwood
authors.affiliation: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
authors.forename: Anna P
authors.initials: AP
authors.lastname: Durbin
authors.affiliation: Emerging Respiratory Virus Section, Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Whitehead
authors.affiliation: Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, USA piersontc@mail.nih.gov.
authors.forename: Theodore C
authors.initials: TC
authors.lastname: Pierson
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D017321:Clinical Trials, Phase I as Topic; D006224:Cricetinae; D003429:Cross Reactions; D003715:Dengue / Q000276:immunology* / Q000821:virology; D003716:Dengue Virus / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D005416:Flavivirus / Q000276:immunology*; D057809:HEK293 Cells; D006801:Humans; D009500:Neutralization Tests; D014709:Vero Cells; D014765:Viral Vaccines / Q000276:immunology*; D014771:Virion / Q000276:immunology; D014838:Volunteers
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000939:Epitopes; D014765:Viral Vaccines
references.citation: Vaccine. 2012 Jun 19;30(29):4301-6
references.pmid: 22682286
references.citation: J Med Virol. 1995 Apr;45(4):451-61
references.pmid: 7666046
references.citation: J Virol. 2001 Aug;75(16):7769-73
references.pmid: 11462053
references.citation: J Virol. 2011 Nov;85(22):12067-72
references.pmid: 21880759
references.citation: Nat Rev Microbiol. 2005 Jan;3(1):13-22
references.pmid: 15608696
references.citation: Cell Host Microbe. 2010 Sep 16;8(3):271-83
references.pmid: 20833378
references.citation: J Virol. 1990 Aug;64(8):3643-53
references.pmid: 1695253
references.citation: Nat Med. 2005 May;11(5):522-30
references.pmid: 15852016
references.citation: Vaccine. 2007 Oct 23;25(43):7559-67
references.pmid: 17869389
references.citation: PLoS Pathog. 2013;9(12):e1003761
references.pmid: 24348242
references.citation: Science. 2008 Mar 28;319(5871):1834-7
references.pmid: 18369148
references.citation: J Virol. 2010 Aug;84(16):8353-8
references.pmid: 20519400
references.citation: AIDS. 2009 Aug 24;23(13):1659-67
references.pmid: 19581791
references.citation: J Gen Virol. 1985 Dec;66 ( Pt 12):2773-6
references.pmid: 4067586
references.citation: Virology. 2006 Mar 1;346(1):53-65
references.pmid: 16325883
references.citation: Lancet. 2012 Nov 3;380(9853):1535-6
references.pmid: 22975339
references.citation: J Biol Chem. 2006 Dec 1;281(48):37183-94
references.pmid: 17001080
references.citation: Curr Top Microbiol Immunol. 2001;260:87-108
references.pmid: 11443883
references.citation: J Virol. 2012 Apr;86(7):3501-12
references.pmid: 22258236
references.citation: PLoS Pathog. 2008 May 09;4(5):e1000060
references.pmid: 18464894
references.citation: New Microbiol. 1995 Oct;18(4):351-8
references.pmid: 8590387
references.citation: Cell Host Microbe. 2007 Apr 19;1(2):135-45
references.pmid: 18005691
references.citation: Virology. 1990 Feb;174(2):450-8
references.pmid: 2154882
references.citation: PLoS Pathog. 2009 May;5(5):e1000453
references.pmid: 19478866
references.citation: Expert Rev Vaccines. 2012 Apr;11(4):427-48
references.pmid: 22551029
references.citation: Antiviral Res. 2013 Jul;99(1):1-5
references.pmid: 23624155
references.citation: N Engl J Med. 2002 Oct 17;347(16):1225-6
references.pmid: 12270973
references.citation: Curr Opin Virol. 2012 Apr;2(2):168-75
references.pmid: 22445964
references.citation: J Biol Chem. 2008 Aug 8;283(32):21899-908
references.pmid: 18559340
references.citation: Nat Rev Microbiol. 2007 Jul;5(7):518-28
references.pmid: 17558424
references.citation: PLoS One. 2012;7(4):e33451
references.pmid: 22509258
references.citation: Nature. 2013 Apr 25;496(7446):504-7
references.pmid: 23563266
references.citation: Nature. 2005 Sep 29;437(7059):764-9
references.pmid: 16193056
references.citation: J Virol. 2009 Jul;83(13):6494-507
references.pmid: 19386704
references.citation: J Virol. 2006 Dec;80(24):12149-59
references.pmid: 17035317
references.citation: Science. 2010 May 7;328(5979):745-8
references.pmid: 20448183
references.citation: PLoS Negl Trop Dis. 2011 Aug;5(8):e1267
references.pmid: 21829748
references.citation: Virology. 1998 Jul 5;246(2):317-28
references.pmid: 9657950
references.citation: Hum Vaccin. 2006 Nov-Dec;2(6):255-60
references.pmid: 17106267
references.citation: Virology. 2011 Feb 5;410(1):30-7
references.pmid: 21084104
references.citation: Adv Virus Res. 2003;59:141-75
references.pmid: 14696329
references.citation: J Virol. 2007 Jun;81(11):6141-5
references.pmid: 17376919
references.citation: Virology. 2008 Nov 10;381(1):67-74
references.pmid: 18801552
references.citation: Lancet. 2008 Feb 9;371(9611):500-9
references.pmid: 18262042
references.citation: Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
references.pmid: 20463105
references.citation: J Virol. 2006 Feb;80(3):1290-301
references.pmid: 16415006
references.citation: PLoS One. 2012;7(12):e52327
references.pmid: 23284988
references.citation: PLoS Pathog. 2011 Jun;7(6):e1002111
references.pmid: 21738473
references.citation: Expert Rev Vaccines. 2011 Mar;10(3):355-64
references.pmid: 21434803
references.citation: J Clin Virol. 2012 Dec;55(4):289-95
references.pmid: 22999801
references.citation: J Gen Virol. 2003 Jan;84(Pt 1):183-191
references.pmid: 12533715
references.citation: Antiviral Res. 2008 Oct;80(1):11-22
references.pmid: 18585795
references.citation: J Clin Microbiol. 2007 Nov;45(11):3777-80
references.pmid: 17804661
references.citation: Cell Host Microbe. 2012 Oct 18;12(4):544-57
references.pmid: 23084921
references.citation: Vaccine. 2011 Aug 11;29(35):6008-16
references.pmid: 21718741
references.citation: Lancet. 2012 Nov 3;380(9853):1559-67
references.pmid: 22975340
references.citation: Epidemiol Infect. 1991 Apr;106(2):205-20
references.pmid: 2019292
references.citation: J Virol. 1994 Jul;68(7):4572-9
references.pmid: 8207831
references.citation: J Gen Virol. 1985 Oct;66 ( Pt 10):2279-83
references.pmid: 2995563
references.citation: Am J Trop Med Hyg. 1952 Jan;1(1):30-50
references.pmid: 14903434
references.citation: Virol J. 2005 Jun 28;2:53
references.pmid: 15985182
references.citation: J Infect Dis. 2007 Dec 15;196(12):1732-40
references.pmid: 18190252